Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limite… (NCT06719700) | Clinical Trial Compass
RecruitingPhase 2
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
China47 participantsStarted 2024-11-30
Plain-language summary
Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed Consent: An informed consent form, signed and dated, must be provided before any steps in the study are performed.
* Age: Males or females aged 18 to 75 years.
* Diagnosis: Histologically or cytologically confirmed small cell lung cancer (SCLC).
* Stage: Stage I-III (AJCC/UICC 8th edition TNM staging), where all lesions can be included in a single radical radiotherapy plan (i.e., limited-stage disease). Stage I-II must be inoperable.
* Life Expectancy: ≥12 weeks.
* Performance Status (PS): WHO PS score of 0 or 1.
* Postmenopausal women or those with a negative urine or serum pregnancy test (HCG sensitivity ≥25 IU/L or equivalent) within 7 days before starting study treatment.
* Female participants must not be breastfeeding.
* Women of childbearing potential (WOCBP) must agree to use contraception during study treatment and for 3 months after the last dose of study drug (i.e., 30 days for an ovulation cycle plus approximately 5 half-lives of the investigational drug).
* Male participants engaging in sexual activity with WOCBP must agree to use contraception during study treatment and for 5 months after the last dose of study drug (i.e., 90 days for sperm regeneration cycle plus approximately 5 half-lives of the investigational drug).
* Males with azoospermia do not need to follow contraception requirements.
* WOCBP who are not sexually active do not need to follow contraception requirements but must still undergo pregnancy testing as outlined.
*…